



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

IJIRSET

International Journal of Innovative Research in
SCIENCE | ENGINEERING | TECHNOLOGY



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 11, Issue 7, July 2022

ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA

Impact Factor: 8.118



9940 572 462



6381 907 438



ijirset@gmail.com



www.ijirset.com

A Short Assessment on Generic and Branded Pills

Rupesh Kumar Pandey, Dr. Kaushal K Chandrul, Dr. Gaurav Kumar Sharma, Dr. Himani Tiwari

B.Pharma Student (4th year), Department of Pharmacy, Mewar University Gangrar, Chittorgarh, India

Dean, Department of Pharmacy, Mewar University Gangrar, Chittorgarh, India

HOD, Department of Pharmacy, Mewar University Gangrar, Chittorgarh, India

Supervisor, Department of Pharmacy, Mewar University Gangrar, Chittorgarh, India

ABSTRACT: Generic pills are the reproduction of branded whose patent has expired branded drug are the unique product that has been developed via pharmaceutical company. They have equal energetic components dosage shape pleasant ling etc. humans normally stressed due to the fact of exceptional in packaging and price. In India humans have many myths about generics due to lack of information and awareness. Doctors normally now not prescribed the generics drug due to the fact of they are extra dubious about exceptional and safety. Pharmacist now not dispenses generics due to the fact of much less fee on sale of generics and much less demand with the aid of peoples. Government was once launched the Jan Aushadhi scheme to presents the qualityofmedicinesataffordablepricetoall. Therearevariousbarriers to pass towards the generics drug in India

KEYWORDS: Generics, Branded, Myths, Perception, Survey, Awareness, Barriers.

I. INTRODUCTION

Generic drugs: According to FDA “a drug product that is similar to branded product is dosage structure power route of administration, best and performance, characteristics, and meant use. It is a reproduction of branded drug whose patent has expired which has no longer one of a kind rights to produce and distribute medicines. Branded drugs: It is the unique product that has been developed with the aid of pharmaceutical company. It has sole proper to manufacture and distribution for a duration of time (patent). A company title drug is a small medicinal drug that’s determined developed and marketed, by using pharmaceutical company. One’s a new drug is discovered, the corporation archives for a patent to guard towards different organizations making copies and promoting the drugs. At this factor the drug has two names - a accepted identify and a manufacturer identify to make it stand out in the market place. Similarity between general and branded tablets

Generic Drugs Vs Branded Drugs: View of Public.....Ghanwat Ashlesha et al 34

- └ It have to comprise identical lively ingredients.
- └ It should have identical dosage form.
- └ They have identical best and overall performance
- └ It should have identical route of administration.
- └ A time-honored pills are protected as branded drug.
- └ It has identical bioavailability. Difference between customary and branded pills
- └ It ought to comprise specific inactive components
- └ Generic capsules are less expensive than branded
- └ They seem to be unique due to distinction in shape, size, colors, marking, in usual and branded medicines.
- └ Branded drug have sole proper (patent) to manufacture and distribution for a duration of time, whilst widely wide-spread drug have no longer any patent on its manufacturing and distribution. Thinking of human beings about familiar pills
- └ It is protected or not?
- └ Why the generics are much less expensive?
- └ If the value of the regularly occurring is low then they may additionally be of inferior quality.
- └ Why they seem different?
- └ Is the generics are fine as branded?

View of Professionals Doctors:

Doctors typically now not prescribed the customary because they are no longer absolutely at ease about protected and effectiveness as in contrast to branded medicines. They have no any fee from producer for prescribing generics like fee on branded. Doctors are additionally fluctuate in their faith closer to and ride with extraordinary medications, clinical history, choice may additionally additionally have an effect on doctor's decision. When the medical doctor prescribed regular drug treatments they do now not supply affected person fitness result as in contrast to branded medicines.

Pharmacist:

They get minimal earnings on sale of generics tablets as in contrast to branded medicines. There is additionally an availability trouble of common drug in Indian market. Less demand of generics by way of customers due to much less fine and result. Patient strictly comply with the prescription which ordinarily incorporate branded medicines. The pharmacist can dispense any company of the capsules when the prescriber writes the common title on a prescription.

Myths and Perception

⌞ A company title drug work better. But this is false, FDA requires typical to be as fantastic as their manufacturer namecounterparts.

⌞ Brand identify drug are safer. The FDA receives very few reviews of detrimental occasions from general making this incorrecttoo.

⌞ Generic use low exceptional of ingredients. No, the energetic substances ought to be equal to the company names.

Jan Aushadhi Scheme:

Making pleasant drug treatments reachable at less expensive expenditures for all, especially the bad and dangers via one-of-a-kind outlets.

Generic Drugs Vs Branded Drugs: View of Public.....Ghanwat Ashlesha et al

35 Generic drugs are moderately priced, as in contrast to the costs of their equal drug treatments in most different countries, but a giant populace of bad human beings in the country, locate it tough to have the funds for the greater costly branded class of medicines. Accordingly, 'ensuring availability of nice drugs at low-priced costs to all', has been a key goal of the Government.

Why scheme being no longer successful?

The Public Health Foundation of India (PHFI) was once requested to find out about the Scheme and recommend remedial measures. PHFI in their document pointed out the following elements which had been basically accountable for the scheme no longer being successful:

- (i) Over dependence on aid from State Government.
- (ii) Poor Supply Chain management.
- (iii) Non-prescription of Generic Medicines by way of the doctors.
- (iv) State Governments launching free provide of drugs.
- (v) Lack of attention amongst the public

After the document authorities has taken various remedial measures to dispose of the issues related with the scheme. Various steps taken with the aid of the authorities are given below:

- a) Increasing the variety of merchandise from 361 to 504 drug treatments and 161 surgical and consumable items. Recently 88 extra pills are delivered to the basket.
- b) Improving the grant chain mechanism thru appointing Distributors and C&F marketers detached States.
- c) Increasing the variety of purposeful stores.
- d) Strengthening the Operating Agency i.e., BPPI via augmenting of man power.
- e) Relaxation in the eligibility criteria of Operating Agency for JAS.

Awareness and Communication

⌞ SMS based facility to help of citizen to finding low price widely wide-spread versions.

⌞ Catalogue shall be kept at stores for reference by way of public.

⌞ Web based facility will also be pastime to find out generic versions.

⌞ Workshops and seminars with medical doctors to disseminate and sensitize them on promotion on protection of low priced regularly occurring drugs.

⌞ Use of social media.

⌞ Adequate courage on print and electronic media

⌞ Education

SURVEY

A survey based totally study in current state of affairs of generic and branded medicines



A survey was once carried out amongst the following team of human beings to comprehend about their opinion closer to the regularly occurring and branded medicines. Literate populace – a hundred humans
Local populace – a hundred humans, Pharmacist-fifty people.

Overview of the Generic Drug Supply Chain

BRAND AND GENERIC DRUGS


When a new drug product is developed and initially marketed, it is protected by a patent, which prevents other companies from marketing a similar product (i.e., based on bioequivalence). These drugs are typically referred to as “branded” or “originator” drugs. Once that protection has expired, other manufacturers may apply to the U.S. Food and Drug Administration (FDA) for approval of their own versions of the drug. “Generic,” or multiple-source drugs, are drugs for which the initial patent protection for the active ingredient has expired. Generic companies can also challenge patents ahead of patent expiration to bring more affordable medicines to patients as early as possible. Congress has provided the first company(ies) to challenge such patents with the potential for 180 days of exclusivity to encourage generics to take on the significant risk and expense of such patent challenges. Generic drugs play an integral role in health care. The expiration of patents and the introduction of multiple generic manufacturers competing against each other on price results in significant cost savings for the health care system. Over the last 10 years, generic manufacturers saved the U.S. health care system an estimated \$253 billion and \$1.67 trillions

A RECENT INDEPENDENT ANALYSIS RAISES IMPORTANT QUESTIONS ON DIFFERENCES BETWEEN THE BRANDED AND GENERIC SUPPLY CHAINS


While branded and customary drugs take comparable paths through the furnish chain, there can be different monetary incentives facing stakeholders. A recent impartial analysis raises numerous questions about the different market incentives various stakeholders face in the manufacturer and generic markets. Notably, the estimated distribution of cash across the stakeholders varies drastically. For example, the producer revenues are responsible for only 36 percentage of the final costs for commonplace products versus greater than seventy six percent for the brand products. In the universal market, half the revenue is taken up by using production cost, while the majority of the ultimate payer cost for generics is determined through other parties in the grant chain (wholesalers, pharmacies, pharmacy benefit managers (PBM), insurers). There are several motives for these differences. Branded manufacturers are responsible for bringing new merchandise to market and take on substantial financial hazard to do so. Branded manufacturers also function in a market where there is no direct price opposition due to regulatory exclusivities and patent protections. There is little room for wholesalers and pharmacies to capture large margins due to their relative lack of negotiating power. Because pharmacy reimbursement for branded pills is tied to a reported price for the product, and there is solely one product available, price fluctuations do not impact pharmacies in the equal way they might in the generic market.

Generic producers take on risk in a different shape than the brands, and instead invest closely to ensure they can demonstrate bioequivalence and incorporate new manufacturing lines. They may additionally also take on significant felony risk by

challenging susceptible brand patents. However, generic producers are competing against multiple producers of the same product, all of which have been approved by using the FDA as bioequivalent. This means that the generic drug market, made up of equal products, experiences competition based totally on cost and ability to provide – giving others in the supply chain, such as pharmacies, wholesalers and group buying organizations, greater ability to negotiate aggressive acquisition costs and maximize their margins. Due to the large wide variety of generic drugs allotted – approximately 89 percent of all prescriptions in the U.S. – even a small margin on a drug can end result in a large source of income due to the volume of product dispensed.



Facts About Generic Medicine



II. CONCLUSION

On the groundwork of above presentation we conclude that when people hear the arguments from both sides, there is relief associated for taking a brand identify drugs because excellent safety and effectiveness. According to pharmacist most of the patient strictly observed prescription which mostly contain branded drug. People are extra doubtful about difference in effectiveness and quality. In India fee on sales of brand identify drug is much higher in furnish chain management. Even if generic medicines are going to made accessible free of cost at the government hospitals the struggle of prices between branded and generic medicinal drug may not give up . It is necessary that policymakers consider the differences inherent in the branded and regularly occurring prescription drugmarkets when considering public policy modifications concerning drug pricing. The differences between the respectivemarkets may additionally require solutions tailored to the precise challenges, rather than a one-size-fits-all solution.

REFERENCES

1. <https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/ucm127615.pdf>.
2. www.cadth.ca/generic-drugs/similarities-and-differences-between-brand-name-and-generic-drugs
3. <https://implementationscience.biomedcentral.com/articles/10.0086/5/3012-017-0556-1>
4. www.amcp.org/prscribing
5. www.restauranthealthcare.com
6. www.ncbi.nlm.nih.gov.in
7. http://janaushadhi.gov.in/about_jan_aushadhi.html
8. <http://www.thehansindia.com/posts/index/Civil-Services/2017-05-09/An-analysis-of-generic-medicines-in-India/298834>
9. Survey conducted by...Government College of pharmacy Karad. Diploma 2ndyear students amongst the 250 people.
10. . Association for Accessible Medicines. 2017 Generic Drug Access & Savings Report. [https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-](https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf)
11. [web2.pdf](https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf)
12. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System (calculated the usage of \$450B prescription spend in 2016 from IMS)
13. Department of Health and Human Resources. Understanding Recent Trends in Generic Drug Prices. ASPE Issue Brief, January 27 2016. <https://aspe.hhs.gov/pdfreport/understanding-recenttrends-generic-drug-prices>. Accessed October 2017.
14. Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021. Report by the Quintiles IMS Institute. May 2017. <http://www.imshealth.com/en/thought-leadership/quintilesimsinstitute/reports/medicines-use-and-spending-in-the-us-review-of-2016-outlook-to-2021> Accessed October 2017.
15. Association for Accessible Medicines. 2017 Generic Drug Access & Savings Report. [https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-](https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf)
16. [web2.pdf](https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf)
17. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System.
18. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System.
19. Academy of Managed Care Pharmacy. AMCP Guide to Pharmaceutical Payment Methods (2013).
20. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System.
21. . Academy of Managed Care Pharmacy. AMCP Guide to Pharmaceutical Payment Methods (2013).
22. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System.
23. For example, Red Oak Sourcing is a joint venture of Cardinal Health, a wholesaler, and CVS Health, a PBM and retail pharmacy chain. <http://redoaksourcing.com/>
24. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System
25. <http://www.drugchannels.net/2016/01/the-top-15-pharmacies-of-2015.html> Accessed October 2017.
26. Academy of Managed Care Pharmacy. AMCP Guide to Pharmaceutical Payment Methods (2013).
27. Academy of Managed Care Pharmacy. AMCP Guide to Pharmaceutical Payment Methods (2013).
28. Sood, N et al. The Flow of Money Through the Pharmaceutical Distribution System.
29. Academy of Managed Care Pharmacy. AMCP Guide to Pharmaceutical Payment Methods (2013)





INNO SPACE
SJIF Scientific Journal Impact Factor
Impact Factor: 8.118



ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 **9940 572 462**  **6381 907 438**  **ijirset@gmail.com**



www.ijirset.com

Scan to save the contact details